Shilpa Medicare Limited (NSE:SHILPAMED)
851.90
-7.55 (-0.88%)
Aug 22, 2025, 3:29 PM IST
Shilpa Medicare Revenue
Shilpa Medicare had revenue of 3.21B INR in the quarter ending June 30, 2025, with 9.90% growth. This brings the company's revenue in the last twelve months to 13.15B, up 11.10% year-over-year. In the fiscal year ending March 31, 2025, Shilpa Medicare had annual revenue of 12.86B with 11.56% growth.
Revenue (ttm)
13.15B
Revenue Growth
+11.10%
P/S Ratio
5.60
Revenue / Employee
13.06M
Employees
1,007
Market Cap
73.73B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 12.86B | 1.33B | 11.56% |
Mar 31, 2024 | 11.53B | 1.01B | 9.64% |
Mar 31, 2023 | 10.52B | -952.56M | -8.31% |
Mar 31, 2022 | 11.47B | 2.45B | 27.21% |
Mar 31, 2021 | 9.02B | -66.41M | -0.73% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 537.77B |
Divi's Laboratories | 96.52B |
Cipla | 274.80B |
Apollo Hospitals Enterprise | 225.51B |
Mankind Pharma | 129.10B |
Zydus Lifesciences | 236.08B |
Fortis Healthcare | 80.94B |
Alkem Laboratories | 133.04B |
Shilpa Medicare News
- 10 days ago - Shilpa Medicare Q1 Results: Revenue rises 9.9% to Rs 321 crore, Net profit jumps over 3x YoY - Business Upturn
- 12 days ago - Shilpa Medicare shares jump 3% after CDSCO approval for NorUDCA tablets - Business Upturn
- 14 days ago - Shilpa Medicare gets CDSCO approval for NorUDCA tablets 500 mg, marks first global clearance for NAFLD treatment - Business Upturn
- 5 weeks ago - Shilpa Medicare shares jump nearly 5% after USFDA issues EIR with VAI for Bengaluru unit - Business Upturn
- 7 weeks ago - Shilpa Medicare subsidiary clears GMP inspection from ANVISA with no major observations - Business Upturn
- 3 months ago - Antique cuts target on Shilpa Medicare to Rs 1,090, retains ‘Buy’ on long-term monetization potential - Business Upturn
- 3 months ago - Top stocks to watch today, May 27: Lupin, Aurobindo Pharma, NHPC, KEC International, Shilpa Medicare and more - Business Upturn
- 3 months ago - Shilpa Medicare subsidiary partners with Orion Corporation to commercialize Recombinant Human Albumin in Europe - Business Upturn